BCMA CAR T cells: The winding path to success

Research output: Contribution to journalReview article

Abstract

Chimeric antigen receptor (CAR) T cells have been shown to successfully treat some hematopoietic malignancies. Recognition of a relevant target on malignant cells and the proper costimulatory molecule are essential for CAR T cell efficacy. In this issue of the JCI, Cohen et al. conducted an early phase trial to evaluate B cell maturation antigen–targeting (BCMA-targeting) CAR T cells in patients with refractory multiple myeloma. Patients who received the highest dose of BCMA-targeting CAR T cells in combination with lymphodepletion had the greatest response. The results of the study provide further support for the use of BCMA-targeting CAR T cells for myeloma, and reiterate the importance of space and cell dose for CAR T cell success.

Original languageEnglish (US)
Pages (from-to)2175-2177
Number of pages3
JournalJournal of Clinical Investigation
Volume129
Issue number6
DOIs
StatePublished - Jun 3 2019

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'BCMA CAR T cells: The winding path to success'. Together they form a unique fingerprint.

  • Cite this